Form 8-K - Current report:
SEC Accession No. 0001159036-26-000035
Filing Date
2026-03-12
Accepted
2026-03-12 08:32:00
Documents
15
Period of Report
2026-03-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K halo-20260312.htm   iXBRL 8-K 34932
2 EX-99.1 davidramsaypressreleasefin.htm EX-99.1 14599
6 GRAPHIC halo-20260312_g1.jpg GRAPHIC 15840
7 GRAPHIC image_0a.jpg GRAPHIC 17552
  Complete submission text file 0001159036-26-000035.txt   223525

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT halo-20260312.xsd EX-101.SCH 1798
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT halo-20260312_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT halo-20260312_pre.xml EX-101.PRE 12522
17 EXTRACTED XBRL INSTANCE DOCUMENT halo-20260312_htm.xml XML 2712
Mailing Address 12390 EL CAMINO REAL SAN DIEGO CA 92130
Business Address 12390 EL CAMINO REAL SAN DIEGO CA 92130 (858) 794-8889
HALOZYME THERAPEUTICS, INC. (Filer) CIK: 0001159036 (see all company filings)

EIN.: 880488686 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32335 | Film No.: 26745773
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)